Project Grant HT94252510878
Award Date 11/1/25
Completion Date 4/30/27
Dollars Obligated $798K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cambridge, MA 02139, USA
Similar Awards
- This Project Grant award for $299,200.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to support the development of a first-in-class small molecule treatment for epithelial ovarian cancer. The award was made on June 1, 2025 to the biotechnology company Microquin LTD, located in Cambridge, Massachusetts, with a target completion date of August 31, 2026. Through this funding, Microquin LTD will focus on advancing innovative...
- The Department of the Army Medical Command awarded a $248,250 Project Grant to Microquin LTD on June 1, 2022 to support the development of a first-in-class therapeutic to treat epithelial ovarian cancer. The work will be performed in Cambridge, MA from June 1, 2022 through May 31, 2023. The grant is being funded through the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research with the goals of transforming military and...
- The Defense Health Agency awarded a $416,115 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Research Institute Of The Mcgill University Health Centre. The grant, awarded on August 15, 2024, will fund the development of next-generation prognostic tools for localized clear cell renal cell carcinoma through the integration of genomic, clinical, and pathological features. The award has a performance period ending on August 14, 2026. The Research...
- This Project Grant award for $5,099,737.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports the development of a novel therapeutic targeting myeloid cells for the treatment of glomerular diseases. The award was made to 149 Bio LLC in Miami, FL and has a period of performance from July 1, 2025 to June 30, 2029. The grant aims to transform healthcare for military service members, veterans, and the broader public by advancing innovative...
- The Defense Health Agency awarded a $464,261 project grant to The Royal Institution For The Advancement Of Learning, a private, non-profit educational institution in Montreal, Canada, to develop the next generation of prognostic tools for localized clear cell renal cell carcinoma. The grant, awarded under the Military Medical Research and Development (CFDA 12.420) program, will fund research to integrate genomic, clinical, and pathological features to create advanced prognostic tools for this...
- The federal Project Grant award of $1,214,375.00 from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), is funding a research project led by Yale University. The project is investigating the use of decoy-resistant IL-18 and immune checkpoint inhibitors in preclinical murine and ex vivo patient-derived models of renal cell carcinoma. The award began on September 15, 2024 and is set to conclude on September 14, 2028. The Military Medical Research...
- The Defense Health Agency awarded a $1,023,225 Project Grant under the Military Medical Research and Development program (CFDA# 12.420) to The Cleveland Clinic Foundation. The grant funds research to investigate the therapeutic relevance of targeting the anti-apoptotic Bcl-xL protein in kidney cancer. A sub-award to Harvard T.H. Chan School of Public Health will perform BH3 profiling to compare apoptotic responses in renal cell carcinomas under varied conditions, including treatment with BH3...
- This $769,073 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research to define and target cancer cell-intrinsic vulnerabilities in renal cell carcinoma. The grant was awarded to the Royal Institution for the Advancement of Learning / McGill Office of Sponsored Research Division, a private university affiliated with McGill University in Montreal, Canada. The research will be conducted from August 1, 2024...
- The Department of the Army Medical Command awarded a $475,457 Project Grant to the Institute of Cancer Research: Royal Cancer Hospital in the United Kingdom. The grant is part of the Military Medical Research and Development program (CFDA 12.420) and will fund research characterizing biomarkers of growth and progression in small renal masses from September 30, 2022 to September 29, 2025. Through this award, the grantee will investigate medical solutions for the battlefield by transforming...
- This federal Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), is providing $1,023,646.00 to Microbiotix, Inc. to develop "oxadiazole inhibitors of bacterial nonstop ribosome rescue" for treating tick-borne diseases like Lyme and tularemia in military personnel, veterans, and civilians. The award commenced on Aug 1, 2025 and is expected to be completed by Jul 31, 2027. Microbiotix, a clinical-stage...